Skip to content
Screener

ADMA Biologics ADMA ASCENIV — Revenue

Other product segments

BIVIGAM
$19.42M-48.5%
Intermediates And Other
$1.3M+41.4%

Similar metrics at other companies

Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%
Oracle logo
ORCLSoftware Revenues — Revenue
$6.82B-2.1%
Blue Owl Capital logo
OWLPerformance revenues — Revenue
$6.07M-3.9%
EAT
EATFranchise revenues — Revenue
$14.7M+21.5%
Cinemark Holdings logo
CNKOther Revenues — Revenue
$113.1M+18.2%
American Electric Power logo
AEPCommercial Revenues — Revenue
$1.21B+15.4%

Other financials

Income statement

See full
Revenue$124.4M+2.0%
Gross profit$86.3M+28.3%
Operating income$52.4M+22.5%
Net income$37.8M+10.5%
EPS (diluted)$0.16+14.3%

Balance sheet

See full
Cash & equivalents$136.0M+50.7%
Total debt$203.9M+1,855%
Total equity$408.2M+2.5%
Total assets$684.2M+22.5%

Cash flow

See full
Operating cash flow$29.5M+39.7%
CapEx$2.3M-6.9%
Free cash flow$27.3M+45.8%

Valuation

See full
Market cap$2.25B-49.1%
Enterprise value$2.32B-46.6%
P/E13.3×-7.9×
P/S4.4×-4.9×

Profitability

See full
Gross margin64.7%+11.7pp
Operating margin43.8%+11.0pp
Net margin33%-11.1pp
FCF margin22.7%+8.9pp

Returns & leverage

See full
Return on equity41.9%-29.3pp
Debt / equity0.5×+0.5×
Current ratio7×+1.6×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:16 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001140361-26-031445
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
(in thousands)
ASCENIV$$102,921$83,321$200,407159,653
BIVIGAM19,41937,71034,84171,222
Intermediates and other(1)1,2979172,1304,790
ADMA BioManufacturing123,637121,948237,378235,665
Plasma Collection Centers723-1,4391,050
License revenue35367171
Total$$124,395$121,984$238,888236,786

Item 1. Financial Statements.

FAQ

What is ADMA Biologics's ASCENIV — revenue?
ADMA Biologics (ADMA) reported ASCENIV — revenue of $102.92M in Q2 2026.
How has ADMA Biologics's ASCENIV — revenue changed year-over-year?
ADMA Biologics's ASCENIV — revenue increased by 23.5% year-over-year, from $83.32M to $102.92M.
What does ASCENIV — revenue mean?
This metric represents the total gross revenue generated from the sale of a specific biopharmaceutical product or therapeutic line after excluding any assessed taxes. It serves as a primary indicator of market adoption, commercial success, and the revenue-generating capacity of the specific product segment within the company's portfolio. Tracking this figure allows investors to evaluate the growth trajectory and competitive positioning of the product in the specialty biologics market.

Ask your AI about ADMA Biologics's asceniv — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude